Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy

Branislav Jeremić; Biljana Milicić

doi:10.1016/j.radonc.2007.12.023

Influence of low-dose daily cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy

Radiother Oncol. 2008 May;87(2):201-3. doi: 10.1016/j.radonc.2007.12.023. Epub 2008 Jan 18.

Authors

Branislav Jeremić¹, Biljana Milicić

Affiliation

¹ Department of Oncology, University Hospital, Kragujevac, Serbia. B.Jeremic@iaea.org

PMID: 18207598
DOI: 10.1016/j.radonc.2007.12.023

Abstract

We investigated the impact of low dose daily cisplatin on distant metastasis-free survival (DMFS) in locally advanced head and neck cancer treated with hyperfractionated radiotherapy (77Gy in 70 fractions in 35 treatment days). In locally controlled tumors cisplatin led to better DMFS (p=0.0272); Cisplatin may have acted independently of micrometastasis in locally advanced H&N cancer.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
Carcinoma, Squamous Cell / radiotherapy*
Cisplatin / administration & dosage*
Combined Modality Therapy
Dose Fractionation, Radiation
Female
Follow-Up Studies
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / pathology
Head and Neck Neoplasms / radiotherapy*
Humans
Male
Neoplasm Metastasis
Radiotherapy Dosage
Survival Rate
Treatment Outcome

Substances

Antineoplastic Agents
Cisplatin